Chad VanDenBerg, Pharm.D., MS, BCPP

Associate Director

Education

  • MS – 2006, Clinical Research Administration – The George Washington University
  • Pharm.D. – 1996 – The University of Arizona

Clinical Interests

  • Alzheimer ’s Disease
  • Cognition
  • Depression
  • Monoamine Oxidase Inhibition

As Associate Director, Dr. VanDenBerg oversees the development and management of clinical trials in both human and companion animals. As an experienced research clinician, he conducts human research under the guidelines of Good Clinical Practice. Dr. VanDenBerg works in collaboration with faculty from the various Colleges at Midwestern University to produce scientifically sound studies with appropriate rationale and endpoints that result in quantifiable outcomes suitable for publication.

Prior to joining MWU, he was an associate professor and Director of the Center for Clinical Research at Mercer University in Atlanta, GA from 2006 to 2014. From 1999 until 2006, Chad was the Director of Clinical Research and Product Information at Somerset Pharmaceuticals, Inc in Tampa, FL where he was part of a team that led to a successful NDA submission. Chad has experience in clinical trial management, Good Clinical Practices (GCP), regulatory affairs, protocol design, and medical writing. As a clinical research scientist he has conducted Phase I through Phase III clinical research trials both as a project manager and as principle investigator.